Pharmakea, Inc.

Sabre Therapeutics LLC

Mannkind Corporation

Fosun Orinove Pharmatech, Inc.

David Gregory Lonergan

John Howard Hutchinson

Martin W Rowbottom

Gary A Flynn

John Bruce Patterson

Peter V Pallai

Qingping Zeng

Timothy Andrew Parr

Kevin Ross Holme

Kevin Duane Bunker

Andiliy Gokching Lai

Imelda Calderon

Jillian Frances Evans

Gretchen Bain

Fei Huang

Qingpeng Zeng

Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.

Autotaxin inhibitor compounds

Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Lysyl oxidase-like 2 inhibitors and uses thereof

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.

Autotaxin inhibitors and uses thereof

Compounds which directly inhibit IRE-1&#x3b1; activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

IRE-1&#x3b1; inhibitors

Heterocyclic vinyl autotaxin inhibitor compounds

Tetracyclic autotaxin inhibitors

Vinyl autotaxin inhibitor compounds

Growing community of inventors

Ventura, CA, United States of America

David Gregory Lonergan